Circulating tumor DNA (ctDNA) is fragmented genetic material originating from dead tumor cells, that can be detected in the plasma and other body fluids of cancer patients. Analysis of ctDNA has emerged as a highly specific method to monitor tumor burden during and after oncologic treatment. The concentration of ctDNA is generally low, but recent development of genetic analysis methods has enabled measurements with increased sensitivity. In many cases, ctDNA has been found in patients with tumors too small to be detected with standard imaging modalities.
The aim of our research is to test the potential of ctDNA as a marker for treatment response and disease recurrence in pediatric oncology. This biomarker could potentially be used to optimize the treatment for each patient, and may thereby reduce the mortality and morbidity of cancer in children.
We run a translational study enrolling children treated for different typed of cancer at Sahlgrenska University Hospital. We have consecutive plasma, white blood cell and urine samples, collected before, during and after treatment, from a large number of patients. We use a range of DNA analysis techniques, including whole genome and exome sequencing as well as novel ultra-sensitive targeted mutation analysis methods.
- Circulating cell-free tumor DNA analysis in pediatric cancers. Andersson D, Fagman H, Dalin MG, Ståhlberg A. (2019) Mol Aspects Med. Sep 25. pii: S0098-2997(19)30091-3. doi: 10.1016/j.mam.2019.09.003.
- Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions.
Dalin MG, Katabi N, Persson M, Lee KW, Makarov V, Desrichard A, Walsh LA, West L, Nadeem Z, Ramaswami D, Havel JJ, Kuo F, Chadalavada K, Nanjangud GJ, Ganly I, Riaz N, Ho AL, Antonescu CR, Ghossein R, Stenman G, Chan TA, Morris LGT. (2017) Nat Commun. Oct 30;8(1):1197. doi: 10.1038/s41467-017-01178-z.
- Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG. (2016) Clin Cancer Res. Sep 15;22(18):4623-33. doi: 10.1158/1078-0432.CCR-16-0637.
More group Martin Dalin publications on PubMed